RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates

被引：23

作者：

Pan, Xiaoyan ^{[1
,2
,3
]}

Shi, Jian ^{[4
]}

Hu, Xue ^{[1
,3
]}

Wu, Yan ^{[1
]}

Zeng, Liang ^{[4
]}

Yao, Yanfeng ^{[3
]}

Shang, Weijuan ^{[1
]}

Liu, Kunpeng ^{[1
,2
]}

Gao, Ge ^{[3
]}

Guo, Weiwei ^{[1
,2
]}

Peng, Yun ^{[3
]}

Chen, Shaohong ^{[1
]}

Gao, Xiaoxiao ^{[3
]}

Peng, Cheng ^{[3
]}

Rao, Juhong ^{[1
,2
]}

Zhao, Jiaxuan ^{[1
,2
]}

Gong, Cheng ^{[4
]}

Zhou, Hui ^{[4
]}

Lu, Yudong ^{[4
]}

Wang, Zili ^{[4
]}

Hu, Xiliang ^{[4
]}

Cong, WenJuan ^{[4
]}

Fang, Lijuan ^{[4
]}

Yan, Yongxiang ^{[4
]}

Zhang, Jing ^{[4
]}

Xiong, Hui ^{[4
]}

Yi, Jizu ^{[4
]}

Yuan, Zhiming ^{[1
,2
,3
]}

Zhou, Pengfei ^{[4
]}

Shan, Chao ^{[1
,2
,3
]}

Xiao, Gengfu ^{[1
,2
,3
]}

机构：

[1] Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan, Hubei, Peoples R China

[2] Univ Chinese Acad Sci, Beijing, Peoples R China

[3] Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, Wuhan, Hubei, Peoples R China

[4] Wuhan YZY Biopharma Co Ltd, Wuhan, Hubei, Peoples R China

来源：

CELL DISCOVERY | 2021年 / 7卷 / 01期

基金：

国家重点研发计划;

关键词：

SARS-COV-2;

D O I：

10.1038/s41421-021-00320-y

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The pandemic of COVID-19 caused by SARS-CoV-2 has raised a new challenges to the scientific and industrious fields after over 1-year spread across different countries. The ultimate approach to end the pandemic is the timely application of vaccines to achieve herd immunity. Here, a novel SARS-CoV-2 receptor-binding domain (RBD) homodimer was developed as a SARS-CoV-2 vaccine candidate. Formulated with aluminum adjuvant, RBD dimer elicited strong immune response in both rodents and non-human primates, and protected mice from SARS-CoV-2 challenge with significantly reducing viral load and alleviating pathological injury in the lung. In the non-human primates, the vaccine could prevent majority of the animals from SARS-CoV-2 infection in the respiratory tract and reduce lung damage. In addition, antibodies elicited by this vaccine candidate showed cross-neutralization activities to SARS-CoV-2 variants. Furthermore, with our expression system, we provided a high-yield RBD homodimer vaccine without additional biosafety or special transport device supports. Thus, it may serve as a safe, effective, and low-cost SARS-CoV-2 vaccine candidate.

引用

页数：15

共 49 条

[21]

Liu Yang, 2021, bioRxiv, DOI 10.1101/2021.03.08.434499

[22] Neutralizing Activity of BNT162b2-Elicited Serum [J].

Liu, Yang ;

Liu, Jianying ;

Xia, Hongjie ;

Zhang, Xianwen ;

Fontes-Garfias, Camila R. ;

Swanson, Kena A. ;

Cai, Hui ;

Sarkar, Ritu ;

Chen, Wei ;

Cutler, Mark ;

Cooper, David ;

Weaver, Scott C. ;

Muik, Alexander ;

Sahin, Ugur ;

Jansen, Kathrin U. ;

Xie, Xuping ;

Dormitzer, Philip R. ;

Shi, Pei-Yong .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (15) :1466-1468

[23] RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response [J].

Liu, Zezhong ;

Xu, Wei ;

Xia, Shuai ;

Gu, Chenjian ;

Wang, Xinling ;

Wang, Qian ;

Zhou, Jie ;

Wu, Yanling ;

Cai, Xia ;

Qu, Di ;

Ying, Tianlei ;

Xie, Youhua ;

Lu, Lu ;

Yuan, Zhenghong ;

Jiang, Shibo .

SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)

[24] Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization [J].

Liu, Zhuoming ;

VanBlargan, Laura A. ;

Bloyet, Louis-Marie ;

Rothlauf, Paul W. ;

Chen, Rita E. ;

Stumpf, Spencer ;

Zhao, Haiyan ;

Errico, John M. ;

Theel, Elitza S. ;

Liebeskind, Mariel J. ;

Alford, Brynn ;

Buchser, William J. ;

Ellebedy, Ali H. ;

Fremont, Daved H. ;

Diamond, Michael S. ;

Whelan, Sean P. J. .

CELL HOST & MICROBE, 2021, 29 (03) :477-+

[25] Immunoglobulin fragment F(ab′)2 against RBD potently neutralizes SARS-CoV-2 in vitro [J].

Pan, Xiaoyan ;

Zhou, Pengfei ;

Fan, Tiejiong ;

Wu, Yan ;

Zhang, Jing ;

Shi, Xiaoyue ;

Shang, Weijuan ;

Fang, Lijuan ;

Jiang, Xiaming ;

Shi, Jian ;

Sun, Yuan ;

Zhao, Shaojuan ;

Gong, Rui ;

Chen, Ze ;

Xiao, Gengfu .

ANTIVIRAL RESEARCH, 2020, 182

[26] Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization [J].

Planas, Delphine ;

Veyer, David ;

Baidaliuk, Artem ;

Staropoli, Isabelle ;

Guivel-Benhassine, Florence ;

Rajah, Maaran Michael ;

Planchais, Cyril ;

Porrot, Francoise ;

Robillard, Nicolas ;

Puech, Julien ;

Prot, Matthieu ;

Gallais, Floriane ;

Gantner, Pierre ;

Velay, Aurelie ;

Le Guen, Julien ;

Kassis-Chikhani, Najiby ;

Edriss, Dhiaeddine ;

Belec, Laurent ;

Seve, Aymeric ;

Courtellemont, Laura ;

Pere, Helene ;

Hocqueloux, Laurent ;

Fafi-Kremer, Samira ;

Prazuck, Thierry ;

Mouquet, Hugo ;

Bruel, Timothee ;

Simon-Loriere, Etienne ;

Rey, Felix A. ;

Schwartz, Olivier .

NATURE, 2021, 596 (7871) :276-+

[27] Spike mutation D614G alters SARS-CoV-2 fitness [J].

Plante, Jessica A. ;

Liu, Yang ;

Liu, Jianying ;

Xia, Hongjie ;

Johnson, Bryan A. ;

Lokugamage, Kumari G. ;

Zhang, Xianwen ;

Muruato, Antonio E. ;

Zou, Jing ;

Fontes-Garfias, Camila R. ;

Mirchandani, Divya ;

Scharton, Dionna ;

Bilello, John P. ;

Ku, Zhiqiang ;

An, Zhiqiang ;

Kalveram, Birte ;

Freiberg, Alexander N. ;

Menachery, Vineet D. ;

Xie, Xuping ;

Plante, Kenneth S. ;

Weaver, Scott C. ;

Shi, Pei-Yong .

NATURE, 2021, 592 (7852) :116-121

[28] Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine [J].

Polack, Fernando P. ;

Thomas, Stephen J. ;

Kitchin, Nicholas ;

Absalon, Judith ;

Gurtman, Alejandra ;

Lockhart, Stephen ;

Perez, John L. ;

Perez Marc, Gonzalo ;

Moreira, Edson D. ;

Zerbini, Cristiano ;

Bailey, Ruth ;

Swanson, Kena A. ;

Roychoudhury, Satrajit ;

Koury, Kenneth ;

Li, Ping ;

Kalina, Warren V. ;

Cooper, David ;

Frenck, Robert W., Jr. ;

Hammitt, Laura L. ;

Tureci, Ozlem ;

Nell, Haylene ;

Schaefer, Axel ;

Unal, Serhat ;

Tresnan, Dina B. ;

Mather, Susan ;

Dormitzer, Philip R. ;

Sahin, Ugur ;

Jansen, Kathrin U. ;

Gruber, William C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (27) :2603-2615

[29] Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial [J].

Ramasamy, Maheshi N. ;

Minassian, Angela M. ;

Ewer, Katie J. ;

Flaxman, Amy L. ;

Folegatti, Pedro M. ;

Owens, Daniel R. ;

Voysey, Merryn ;

Aley, Parvinder K. ;

Angus, Brian ;

Babbage, Gavin ;

Belij-Rammerstorfer, Sandra ;

Berry, Lisa ;

Bibi, Sagida ;

Bittaye, Mustapha ;

Cathie, Katrina ;

Chappell, Harry ;

Charlton, Sue ;

Cicconi, Paola ;

Clutterbuck, Elizabeth A. ;

Colin-Jones, Rachel ;

Dold, Christina ;

Emary, Katherine R. W. ;

Fedosyuk, Sofiya ;

Fuskova, Michelle ;

Gbesemete, Diane ;

Green, Catherine ;

Hallis, Bassam ;

Hou, Mimi M. ;

Jenkin, Daniel ;

Joe, Carina C. D. ;

Kelly, Elizabeth J. ;

Kerridge, Simon ;

Lawrie, Alison M. ;

Lelliott, Alice ;

Lwin, May N. ;

Makinson, Rebecca ;

Marchevsky, Natalie G. ;

Mujadidi, Yama ;

Munro, Alasdair P. S. ;

Pacurar, Mihaela ;

Plested, Emma ;

Rand, Jade ;

Rawlinson, Thomas ;

Rhead, Sarah ;

Robinson, Hannah ;

Ritchie, Adam J. ;

Ross-Russell, Amy L. ;

Saich, Stephen ;

Singh, Nisha ;

Smith, Catherine C. .

LANCET, 2020, 396 (10267) :1979-1993

[30] Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial [J].

Richmond, Peter ;

Hatchuel, Lara ;

Dong, Min ;

Ma, Brenda ;

Hu, Branda ;

Smolenov, Igor ;

Li, Ping ;

Liang, Peng ;

Han, Htay Htay ;

Liang, Joshua ;

Clemens, Ralf .

LANCET, 2021, 397 (10275) :682-694

← 1 2 3 4 5 →